Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371724 | 1.00 | LMNA (0.31) | LMNAMAPTHTT | |
| SCHEMBL12903081 | 1.00 | LMNA (0.31) | LMNAMAPTHTT | |
| SCHEMBL25050617 | 0.85 | — | — | |
| SCHEMBL24410958 | 0.85 | — | — | |
| SCHEMBL24410797 | 0.85 | — | — | |
| SCHEMBL24410795 | 0.85 | — | — | |
| SCHEMBL24410794 | 0.85 | — | — | |
| SCHEMBL22062797 | 0.82 | — | — | |
| SCHEMBL19491922 | 0.81 | — | — | |
| SCHEMBL24330287 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067662-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-02-29 | — | — | US | disclosed |
| US-20240067662-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-02-29 | — | — | US | disclosed |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230322756-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322756-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-11771697-B2 | Small molecule degraders of polybromo-1 (PBRM1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230212140-A1 | GLP-1 RECEPTOR AGONIST AND USE THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-07-06 | — | — | US | disclosed |
| US-20230212170-A1 | INHIBITORS OF KRAS G12C PROTEIN AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-07-06 | — | — | US | disclosed |
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | GENZYME CORPORATION | 2020-04-02 | — | — | US | disclosed |
| US-20190276465-A1 | Nitrogen-Containing Heterocyclic Compounds As FXR Modulators | Hepagene Therapeutics (HK) Limited (HK) | 2019-09-12 | — | — | US | disclosed |
| US-10227357-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20140128390-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-05-08 | — | — | US | disclosed |
| US-8404687-B2 | Disubstituted phthalazine hedgehog pathway antagonists | ELI LILLY AND COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-8334382-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2012-12-18 | — | — | US | disclosed |
| US-20110190304-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION | 2011-01-06 | — | — | US | disclosed |
| US-7662830-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2010-02-16 | — | — | US | disclosed |
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276465-A1 | Nitrogen-Containing Heterocyclic Compounds As FXR Modulators | NR1H4, FXR1, FXR2 | LMNA 3466/4885MAPT 3342/4885HTT 644/4885 |
| US-10227357-B2 | Compounds and methods for kinase modulation, and indications therefor | KIT, PRKCH, PRKACA | LMNA 1232/4885MAPT 3807/4885HTT 2961/4885 |
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | GPR88, PIGO, PRLHR | LMNA 2783/4885MAPT 4066/4885HTT 3390/4885 |
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | MAN2B1, GAA, GBA1 | LMNA 2419/4885MAPT 607/4885HTT 963/4885 |
| US-20230322756-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | GLP1R, GIPR, VIP | LMNA 3067/4885MAPT 4126/4885HTT 3758/4885 |
| US-11760744-B2 | Fused ring compounds | KRAS, NRAS, HRAS | LMNA 3608/4885MAPT 3269/4885HTT 3961/4885 |
| US-11771697-B2 | Small molecule degraders of polybromo-1 (PBRM1) | PBRM1, SMARCC1, SMARCC2 | LMNA 1431/4885MAPT 1076/4885HTT 636/4885 |
| US-20230212140-A1 | GLP-1 RECEPTOR AGONIST AND USE THEREOF | GLP1R, GIPR, GPR119 | LMNA 4309/4885MAPT 4070/4885HTT 2918/4885 |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | ADRM1, CD79B, BRDT | LMNA 2374/4885MAPT 532/4885HTT 3349/4885 |
| US-20110190304-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | SHH, GLI1, SMO | LMNA 4858/4885MAPT 3122/4885HTT 1781/4885 |
| US-20230212170-A1 | INHIBITORS OF KRAS G12C PROTEIN AND USES THEREOF | KRAS, NRAS, HRAS | LMNA 3151/4885MAPT 3275/4885HTT 1576/4885 |
| US-20240067662-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | LMNA 3908/4885MAPT 3872/4885HTT 2804/4885 |
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | PIGO, GPR52, GPR88 | LMNA 3266/4885MAPT 4200/4885HTT 2614/4885 |
| US-20140128390-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | KIT, PRKCH, PRKACA | LMNA 1232/4885MAPT 3807/4885HTT 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.